Delcath Systems Inc (DCTH)

Currency in USD
11.410
0.000(0.00%)
Closed·
Pre Market
11.420+0.010(+0.09%)
·
DCTH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 8 days
Fair Value
Day's Range
11.35011.674
52 wk Range
7.17018.230
Key Statistics
Prev. Close
11.41
Open
11.44
Day's Range
11.35-11.674
52 wk Range
7.17-18.23
Volume
588.76K
Average Volume (3m)
677.95K
1-Year Change
31.15%
Book Value / Share
2.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DCTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.078
Upside
+111.03%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Delcath Systems Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Delcath Systems Inc Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Delcath Systems Inc Earnings Call Summary for Q1/2025

  • Delcath Systems Q1 2025 EPS of $0.03 and revenue of $19.8M beat forecasts; shares surge 15.18%
  • Net income improved to $1.1M from $11.1M loss; gross margins up to 86% from 71% in 2024
  • Company aims to activate 30 treatment centers by year-end; plans to increase SG&A by 60% and R&D by 150%
  • CEO confident in growth trajectory; highlights potential impact of clinical trial data on progression-free survival
  • Analysts set price targets between $21-$25; stock delivered 110.52% return over past year
Last Updated: 08/05/2025, 14:40
Read Full Transcript

Compare DCTH to Peers and Sector

Metrics to compare
DCTH
Peers
Sector
Relationship
P/E Ratio
−27.2x−4.4x−0.5x
PEG Ratio
−0.34−0.280.00
Price/Book
4.8x2.9x2.6x
Price / LTM Sales
7.2x3.4x3.2x
Upside (Analyst Target)
104.0%37.1%41.2%
Fair Value Upside
Unlock1.7%6.2%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.078
(+111.03% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
0.03 / 0.02
Revenue / Forecast
19.80M / 15.51M
EPS Revisions
Last 90 days

DCTH Income Statement

People Also Watch

14.67
OSCR
+1.52%
107.95
CRDO
+6.65%
54.220
ASTS
-0.21%
35.11
BMNR
-11.78%
124.05
ALAB
+1.49%

FAQ

What Stock Exchange Does Delcath Systems Trade On?

Delcath Systems is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Delcath Systems?

The stock symbol for Delcath Systems is "DCTH."

What Is the Delcath Systems Market Cap?

As of today, Delcath Systems market cap is 388.47M.

What Is Delcath Systems's Earnings Per Share (TTM)?

The Delcath Systems EPS (TTM) is -0.46.

When Is the Next Delcath Systems Earnings Date?

Delcath Systems will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is DCTH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Delcath Systems Stock Split?

Delcath Systems has split 5 times.

How Many Employees Does Delcath Systems Have?

Delcath Systems has 96 employees.

What is the current trading status of Delcath Systems (DCTH)?

As of 29 Jul 2025, Delcath Systems (DCTH) is trading at a price of 11.41, with a previous close of 11.41. The stock has fluctuated within a day range of 11.35 to 11.67, while its 52-week range spans from 7.17 to 18.23.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.